Rechallenge, Potential Drug Induced Liver Injury (Kaiser)
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Drug re-administration or rechallenge should be avoided after drug-induced liver injury
(DILI) to avoid recurrent and fatal injury. Rechallenge outcomes vary considerably by drug
and patient subjects. In order to better predict these outcomes, the objective of this
analysis is to assess clinical outcomes of positive drug rechallenge following possible
drug-induced liver injury. Electronic medical records from Kaiser Permanente California
(KPSC), a managed care organization, will be utilized to identify patients who experience
possible drug-induced liver injury following exposure to medications associated with
hepatotoxicity, and who are then rechallenged with the medication.